NEWS

Written By: Jeff Engle, PharmD, MS, M Health Fairview University of Minnesota Medical Center Download Here The purpose of this PQI is to discuss the clinical considerations around the use of tafasitamab-cxix (Monjuvi®) to optimize the outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Background: DLBCL is an aggressive lymphoma and is the […]

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea LOS ANGELES, Calif., July 1, 2021 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug […]

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now Testing Program, an Epizyme […]

FOR IMMEDIATE RELEASE June 29th 2021   STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org LOUISIANA SIGNS LAW TO PROHIBIT WHITE BAGGING June has been filled with announcements and progress in the world of oncology at state legislatures throughout the […]

CONTACTS: Jacquie Ross, Investors (650) 358-1054 Mary Lynn Carver, Media (410) 443-1853   For Immediate Release KITE ANNOUNCES YESCARTA® CAR T-CELL THERAPY IMPROVED EVENT-FREE SURVIVAL BY 60% OVER CHEMOTHERAPY PLUS STEM CELL TRANSPLANT IN SECONDLINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA — Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial […]

WHIPPANY, N.J., June 23, 2021 – Bayer announced the availability of new packaging for the company’s treatment Stivarga® (regorafenib) to support dispensing. Stivarga is now available in four 21-count bottles, replacing the previous packaging of three 28-count bottles.   “The new packaging contains four 21-count bottles to help further accommodate dispensing of Stivarga,” said Ray Bailey, RPh, […]

FOR IMMEDIATE RELEASE June 18th 2021 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org NORTH CAROLINA PUSHING TO ENHANCE CONTINUITY OF CARE Earlier this week the North Carolina Senate unanimously approved a bill to regulate Pharmacy Benefit Managers and provide […]

June 16, 2021 at 3:50 PM EDT — First precision therapy that specifically targets the primary driver of the disease —— Durable clinical responses, including complete remissions, shown in patients with or without prior treatment —— Full approval supported by robust efficacy and safety data from two clinical trials —— Blueprint Medicines to host investor […]

FOR IMMEDIATE RELEASE 6/11/21 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org NEW YORK STATE PUSHES ONCOLOGY MOMENTUM FORWARD             The legislative victories continue to pile up, recently we have seen major victories in Texas, Tennessee and now in […]

NEWTON, Mass., June 3, 2021 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, are now commercially available. The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) […]

FOR IMMEDIATE RELEASE 6/8/21 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org TENNESSEE REGULATES PBM; WIN FOR ONCOLOGY PATIENTS             NCODA was thrilled to announce the major legislative victory in the state of Texas that regulates Pharmacy Benefit Managers (PBMs). […]